YTYoshiaki Tomiyama

Yoshiaki Tomiyama

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Yoshiaki Tomiyama has a total of 236 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Complement activation profile in adult primary immune thrombocytopenia

    by Keiichi Nakata, Ichio Onami, Hisashi Kato, Satoru Kosugi, Yoshiaki Tomiyama, Hiroaki Matsushita, Atsuo Kurata, Kazuki Sato, Kasumi Takahashi, Fumie Sawamura, et al.

    Complement activation has been reported in primary immune thrombocytopenia (ITP); however, its clinical relevance remains poorly understood. This study aimed to clarify the association between complement activation and various biomarkers and the clinical characteristics of patients with ITP. A total of 40 patients with ITP were enrolled in this study. Platelet-bound C1q, C3d, and C4d were elevated in a substantial population of patients with ITP compared with healthy controls with highly variable titers. Hierarchical clustering analysis showed that patients with ITP could be classified into the following 3 groups according to their levels: all negative (cluster 1), elevated C1q with negative to low C3d and C4d (cluster 2), and high C3d and C4d (cluster 3). Platelet-associated (PA) immunoglobulin M (IgM) was detected mostly in cluster 3, and PA-IgG was detected in clusters 2 and 3. The number of cases refractory to first-line therapy increased in clusters 2 and 3. Complement deposition on the platelet surface correlated with an increased percentage of immature platelets. There was no significant association between complement activation and PA glycoprotein IIb/IIIa (GPIIb/IIIa) or PA-GPIb/IX antibodies, C1s ratio in the plasma, and fatigue score. Our results suggest that PA-IgG and PA-IgM contribute differentially to the complement activation profile on the platelet surface and are associated with increase in platelet turnover, characterizing a distinct subset of patients with ITP with complement activation. Our findings also may provide a rationale for stratifying patients in future clinical trials of complement-targeted therapies.


  • Open Access

    Exploring the Burden on Patients Living With and Receiving Treatment for Immune Thrombocytopenia ( ITP ): Patient and Physician Perceptions From the ITP World Impact Survey (I‐ WISh ) 2.0

    by Nichola Cooper, James Bussel, Waleed Ghanima, Drew Provan, Yoshiaki Tomiyama, Ming Hou, Donald M. Arnold, Cristina Santoro, Francesco Zaja, Barbara Lovrencic, et al.

    Limited data exist on how patients and physicians perceive immune thrombocytopenia (ITP) symptoms and treatment‐related burden. I‐WISh (ITP World Impact Survey) 2.0 surveyed 1018 patients and 431 physicians in 15 countries to characterize the impact of ITP and its treatments on patients. Approximately one‐third of patients reported that ITP had a high impact on daily activities and family/social life, and 54% reported that it had a high impact on emotional wellbeing. Patients and physicians generally aligned on symptoms and treatment goals, but more patients (48%) than physicians (29%) reported fatigue as common and problematic. Ninety‐seven percent of patients reported that they had received treatment for ITP, most commonly corticosteroids. Most patients and 54% of physicians were satisfied with available treatments, although patients reported treatment‐related burdens. Twenty‐eight percent confirmed they would have chosen a different treatment. Two‐thirds of patients were in a stable, sustained remission, and most had never paused treatment (67%). Nevertheless, two‐thirds of patients preferred limiting time on treatment and/or not being on lifelong treatment. I‐WISh 2.0 emphasizes the extensive disease and treatment burden faced by patients living with ITP, especially the impact of fatigue. It also reminds us that shared decision‐making is needed to ensure treatment goals are aligned with patient expectations, including health‐related quality of life.

  • Open Access

    Addition of romiplostim to immunosuppressive therapy as first-line treatment for patients with aplastic anemia

    by Jong Wook Lee, Jun Ho Jang, Hirohito Yamazaki, Masashi Sawa, Masahiro Kizaki, Yoshiaki Tomiyama, Koji Nagafuji, Kensuke Usuki, Jyh-Pyng Gau, Yasuyoshi Morita, et al.


  • Open Access

    Correction: A phase 3 study of the efficacy and safety of avatrombopag in Japanese adults with chronic immune thrombocytopenia

    by Hiroki Yamaguchi, Masaki Iino, Shugo Kowata, Ryusuke Yamamoto, Jun Yamanouchi, Yutaka Imamura, Keita Kirito, Kenji Yokoyama, Tomoki Ito, Tatsunori Ishikawa, et al.

  • Open Access

    A phase 3 study of the efficacy and safety of avatrombopag in Japanese adults with chronic immune thrombocytopenia

    by Hiroki Yamaguchi, Masaki Iino, Shugo Kowata, Ryusuke Yamamoto, Jun Yamanouchi, Yutaka Imamura, Keita Kirito, Kenji Yokoyama, Tomoki Ito, Tatsunori Ishikawa, et al.

    Avatrombopag is an oral thrombopoietin receptor agonist approved widely for the treatment of adults with chronic immune thrombocytopenia (ITP). However, data in Japanese patients are limited. This confirmatory phase 3, open-label study investigated avatrombopag (initial dose 20 mg/day) in Japanese adults (aged ≥ 18 years) with chronic ITP (≥ 12 months), insufficient response to prior treatment and an average of 2 platelet counts (PCs) < 30 × 109/L. The primary endpoint was the cumulative number of weeks of platelet response (PC ≥ 50 × 109/L) without rescue therapy for bleeding. Secondary endpoints included platelet response rate at Day 8 and safety. In total, 19 patients were enrolled into the 26-week core phase. The mean age was 56.0 years; 78.9% of patients were female. Mean cumulative number of weeks of platelet response was 13.5 (95% CI 9.1–17.8). Platelet response at Day 8 was achieved by 63.2% of patients. In the core phase, adverse events (AEs) occurred in 94.7% of patients and serious AEs in 15.8%. No thromboembolic events or deaths occurred in the core phase. Avatrombopag demonstrated a rapid and durable platelet response and was well tolerated in Japanese patients with chronic ITP. Long-term safety and efficacy are being assessed in the ongoing extension phase.


  • Open Access

    Long-term safety and efficacy of fostamatinib in Japanese patients with primary immune thrombocytopenia

    by Masataka Kuwana, Yoshiaki Tomiyama

    Fostamatinib had superior efficacy to a placebo and acceptable safety profiles for at least 1 year in a phase 3 study of Japanese patients with primary immune thrombocytopenia. Here, we report the 3-year safety and efficacy of fostamatinib in that study. Data from 33 patients who received at least one dose of fostamatinib were analyzed. A platelet response > 50,000/µL (at two consecutive visits at least 28 days apart while receiving fostamatinib) was achieved in 16 patients (48%). The median total duration of a platelet response > 50,000/µL was 589 (range: 106–1003) days. Gastrointestinal disorders, such as diarrhea, hypertension, and hepatic enzyme elevation, were the most common fostamatinib-related adverse events. Most events occurred within 12 weeks of treatment. No thromboembolisms, treatment-related infections, or moderate or severe treatment-related bleeding events were observed. In summary, this extension study of a clinical trial found a sustained platelet response without new safety signals during 3-year treatment with fostamatinib.


  • Haematopoietic regeneration by HLA‐A*0206‐deficient clones in severe aplastic anaemia without definitive immunosuppressive treatment

    by Yoshitaka Zaimoku, Kazuya Sakai, Noriaki Tsuji, Kazuyoshi Hosomichi, Shinya Yamada, Dung Cao Tran, Miku Kobayashi, Ayana Sugiyama, Kouyuki Hirayasu, Hiroki Mizumaki, et al.

    Summary: We describe the case of a 74‐year‐old man with severe aplastic anaemia who experienced persistent remission attributed to proliferation of HLA allele‐deficient clones. Despite an initial worsening of pancytopenia with eltrombopag and ciclosporin treatment, gradual trilineage haematopoietic recovery occurred, with blood counts normalizing over 3 years. Flow cytometry and deep nucleotide sequencing revealed that haematopoiesis was primarily supported by several clones with somatic mutations that inactivated antigen presentation via HLA‐A*0206. This suggests that monitoring haematopoietic regeneration by immune escape clones could be an alternative approach for immune aplastic anaemia patients who possess HLA allele‐deficient clones and cannot tolerate standard therapy.


  • Comparison of platelet transfusion effectiveness between Helicobacter pylori‐positive and ‐negative immune thrombocytopenia

    by Shotaro Tabata, Hiroki Hosoi, Ke Wan, Ayaka Sakaki, Toshiki Mushino, Shogo Murata, Yoshiaki Tomiyama, Takashi Sonoki

    Summary: Immune thrombocytopenia (ITP) is characterized by early platelet destruction and impaired platelet production. Helicobacter pylori (H. pylori) infection seems to contribute to the pathogenesis in certain ITP patients in Japan. We compared the effectiveness of platelet transfusion in severe ITP in the presence or absence of H. pylori. The median corrected count increment (CCI) at 24 h after platelet transfusion (CCI‐24) of the H. pylori‐positive ITP patients was higher than that of the H. pylori‐negative ITP patients (6463 vs. 754, p < 0.001), and the CCI‐1 was also in the same direction but not significant (23 351 vs. 11 578). Multiple regression analyses showed that H. pylori infection was independently associated with CCI‐24. Our study suggests that platelet transfusion may be more effective in H. pylori‐positive ITP patients.


  • Open Access

    Long‐term treatment with fostamatinib in Japanese patients with primary immune thrombocytopenia: An open‐label extension study following a phase 3 placebo‐controlled, double‐blind, parallel‐group study

    by Masataka Kuwana, Tomoki Ito, Shugo Kowata, Yoshihiro Hatta, Katsumichi Fujimaki, Kensuke Naito, Shingo Kurahashi, Toshiya Kagoo, Kazuki Tanimoto, So Saotome, et al.


  • FNAIT pathogenesis determined by serial analysis of three subsequent pregnancies of a woman with severe fetal and neonatal alloimmune thrombocytopenia (FNAIT) with anti-HPA-4b and anti-HPA-5b alloantibodies in the first sibling

    by Tomoko Kiyokawa, Kazuya Mimura, Keisuke Nagamine, Kotarosumitomo Nakayama, Mikiko Horiuchi, Tamayo Morikawa, Mika Hosokawa, Mayumi Nakao, Masayuki Endo, Tadashi Kimura, et al.

    Background Fetal and neonatal alloimmune thrombocytopenia (FNAIT) is caused by anti-HPA alloantibody, and anti-HPA-4b is the most common cause in Japanese. Anti-HPA-5b is frequently detected in pregnant women, but it is still controversial whether anti-HPA-5b causes severe FNAIT. Case presentation A Japanese woman with anti-HPA-4b and anti-HPA-5b alloantibodies delivered a baby with severe FNAIT who was both HPA-4b and HPA-5b incompatible. We carefully monitored the patient’s following three pregnancies (the second and the fourth siblings were HPA-4b incompatible and HPA-5b compatible; the third sibling was both HPA-4b and HPA-5b compatible). FNAIT was not observed in all three siblings, although a modest decrease in cord blood platelet count was observed in the HPA-4b incompatible siblings compared to the HPA-4b compatible sibling. Serial monitoring of anti-HPA titer showed that anti-HPA-4b markedly decreased in late pregnancy and recovered after delivery of the HPA-4b incompatible siblings, but these decreases were not observed during the mother’s pregnancy with the HPA-4b compatible sibling. In contrast, anti-HPA-5b remained at a high titer during pregnancy with all three siblings. Conclusion Our data indicate that dynamic changes of anti-HPA-4b occur during pregnancy and strongly suggest that anti-HPA-5b was mainly responsible for severe FNAIT in this case.